<DOC>
	<DOC>NCT03064282</DOC>
	<brief_summary>Treatment of patients with prostatic hyperplasia with topical papaverine.</brief_summary>
	<brief_title>Prostatic Hyperplasia Treatment and Cancer Prevention</brief_title>
	<detailed_description>Patients with obstructive voiding and high PSA to be studied for the regression of symptoms and declining PSA.</detailed_description>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Papaverine</mesh_term>
	<criteria>patients with symptoms e.g. obstructive voiding, hyperplasia and high PSA patients on chemotherapy abnormal lab values e.g. liver function, GFR and CAD</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>